Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib

Overview of attention for article published in JAMA Oncology, April 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
Above-average Attention Score compared to outputs of the same age and source (51st percentile)

So far, Altmetric has seen 3 public wall posts from 1 users.

This retrospective analysis suggests that osimertinib may be more potent than rociletinib at clinical doses in patients exposed…

This case series of 9 EGFR mutation-positive patients with lung cancer who have progressed on the third generation EGFR…

This retrospective analysis suggests that osimertinib may be more potent than rociletinib at clinical doses in patients exposed…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.